Osteoporosis in real clinical practice: focus on alfacalcidol
- Authors: Toroptsova N.V1, Nikitinskaya O.A1
-
Affiliations:
- FSBIS “Scientific Research Institute of Rheumatology n.a.V.A. Nasonova"
- Issue: No 19 (2016)
- Pages: 36-41
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289483
- ID: 289483
Cite item
Open Access
Access granted
Abstract
The article presents the results of survey of physicians of 6 specialties involved in the treatment of osteoporosis, and patients suffering from this disease. A survey of doctors has showed that they appoint alfacalcidol to 27% of patients, including as a monotherapy in 8% of cases. Among patients, 25% of the respondents received alfacalcidol in combination with other drugs for the treatment of osteoporosis (22%), or as monotherapy (3%). In addition, article presents the analysis of the literature, which is justified the advantages of alfacalcidol from the perspective of evidence-based medicine.
Keywords
Full Text
About the authors
N. V Toroptsova
FSBIS “Scientific Research Institute of Rheumatology n.a.V.A. Nasonova"
Email: torop@irramn.ru
Laboratory of Osteoporosis
O. A Nikitinskaya
FSBIS “Scientific Research Institute of Rheumatology n.a.V.A. Nasonova"MD, Head of Laboratory of Osteoporosis
References
- Boonen S., Vanderschueren D., Haentjens P., Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J. Intern. Med. 2006;259:539-52.
- Mehsen N., Paccou J., Confavreux C.B., David C., Leboime A., Laroche M. Management of patients with incident fractures during osteoporosis treatment. Joint Bone Spine. 2010;77(2):133-38.
- Nuti R., Bianchi G., Brandi M.L., Caudarella R., D'Erasmo E., Fiore C., Isaia G.C., Luisetto G., Muratore M., Oriente P., Ortolani S. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol. Int. 2006;26(5):445-53.
- Ringe J.D., Farahmand P., Schacht E. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. Rheumatol. Int. 2013;33(3):637-43.
- Ringe J.D., Dorst A., Faber H., Schacht E., Rahlfs V.W. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol. Int. 2004;24(2):63-70.
- Ringe J.D., Faber H., Fahramand P., Schacht E. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J. Rheumatol. 2005;76(Suppl.):33-40.
- Richy F., Ethgen O., Bruyere O., Reginster J.Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos. Int. 2004;15(4):301-10.
- de Nijs R.N., Jacobs J.W., Algra A., Lems W.F., Bijlsma J.W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos. Int. 2004;15(8):589-602.
- Ringe J.D., Farahmand P., Schacht E., Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol. Int. 2007;27(5):425-34.
- Felsenberg D., Bock O., Börst H., Armbrecht G., Beller G., Degner C., Stephan-Oelkers M., Schacht E., Mazor Z., Hashimoto J., Roth H.J., Martus P., Runge M. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J. Musculoskelet Neuronal Interact. 2011;11(1): 34-45.
- Richy F., Dukas L., Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif. Tissue Int. 2008;82(2):102-7.
- Dukas L., Schacht E., Mazor Z., Stаhelin H.B. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/ min. Osteoporos. Int. 2005;16(2):198-203.
- Ito S., Harada A., Kasai T., Sakai Y., Takemura M., Matsui Y., Hida T., Ishiguro N. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: an investigation using a patient database. Geriatr. Gerontol. Int. 2014;14(Suppl 1):122-28.
- Scharla S.H., Schacht E., Bawey S., Kamilli I., Holle D., Lempert U.G. Pleiotropic effect of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr. Rheum. 2003;23:268-74.
- Ringe J.D., Schacht E. Naturliches Vitamin D oder Alfacalcidol als Folgebehandlung langjahriger Bisphosphonat-Therapie bei postmenopausaler Osteoporose. Osteology. 2012;21:83-7.
- Orimo H. Clinical Application of 1a(OH) D3 in Japan. Akt Rheumatol. 1994;19:27-30.
- Avenell A., Gillespie W.J., Gillespie L.D., O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst. Rev. 2009;2:CD000227.
Supplementary files
